- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06212102
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation: A Randomized Controlled Non-inferiority Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Usama M Fouda, Prof.
- Phone Number: +201095401375
- Email: umfrfouda@yahoo.com
Study Locations
-
-
-
Giza, Egypt
- Bedaya Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients belonging to Poseidon group 4
Exclusion Criteria:
- PCOS
- Endometriosis
- History of recurrent abortion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Progestin primed ovarian stimulation group
HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS. In subsequent cycle, frozen embryo transfer was done |
HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS).
Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
|
Active Comparator: GnRH antagonist group
HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS. In subsequent cycle, frozen embryo transfer was done |
HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS).
Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medications costs per retrieved oocyte
Time Frame: Ten to fifteen days after starting ovarian stimulation]
|
Total cost of medications used in all cycles/number of retrieved oocytes
|
Ten to fifteen days after starting ovarian stimulation]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical pregnancy rate
Time Frame: 5 weeks after embryo transfer]
|
Presence of intrauterine gestational sac detected by transvaginal ultrasound
|
5 weeks after embryo transfer]
|
Ongoing Pregnancy Rate
Time Frame: 18 weeks after embryo transfer]
|
Pregnancies continued beyond 20 weeks gestation
|
18 weeks after embryo transfer]
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ismail Aboul Foutouh, Prof., Cairo University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Double stimulation
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey
Clinical Trials on Progestin primed ovarian stimulation
-
Shanghai First Maternity and Infant HospitalThe University of Hong KongCompleted
-
Zagazig UniversityRecruitingFertility Issues | Ovary CystEgypt
-
Kaohsiung Veterans General Hospital.CompletedFertilization in VitroTaiwan
-
ANDROFERT - Clinica de Andrologia e Reproducao...Completed
-
University Hospital, BrestTerminatedCardiovascular Diseases | Embolism and Thrombosis | Ovarian Hyperstimulation SyndromeFrance
-
Tu Du HospitalFederico II University; University of Medicine and Pharmacy at Ho Chi Minh...Recruiting
-
Istituto Clinico HumanitasCompletedFertility Disorders | ART
-
IBSA Institut Biochimique SACompleted
-
Dr Massin NathalieCompleted